J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes

Johnson & Johnson cites the 2005 switch to the ASP-plus 6% reimbursement model among its reasons for optimism despite Procrit’s recent performance. Aranesp is gaining on J&J brand; Procrit market share slipped to 61% in second quarter.